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Abstract
Genome-wide association studies (GWAS) have reproducibly associated variants within introns of 
FTO with increased risk for obesity and type-2 diabetes (T2D) 1–3. While the molecular 
mechanisms linking these noncoding variants with obesity are not immediately obvious, 
subsequent studies in mice demonstrated that FTO expression levels influence body mass and 
composition phenotypes 4–6. Yet, no direct connection between the obesity-associated variants and 
FTO expression or function has been made 7–9. Here, we show that the obesity-associated 
noncoding sequences within FTO are functionally connected, at megabase distances, with the 
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homeobox gene IRX3. The obesity-associated FTO region directly interacts with the promoters of 
IRX3 as well as FTO in the human, mouse, and zebrafish genomes. Furthermore, long-range 
enhancers within this region recapitulate aspects of IRX3 expression, suggesting that the obesity-
associated interval belongs to the regulatory landscape of IRX3. Supporting this, obesity-
associated SNPs are associated with expression of IRX3, but not FTO, in human brains. Directly 
linking IRX3 expression with regulation of body mass and composition, Irx3-deficient mice 
exhibit a 25–30% reduction in body weight, primarily through the loss of fat mass and increase in 
basal metabolic rate with browning of white adipose tissue. Furthermore, hypothalamic expression 
of a dominant negative form of Irx3 reproduces the metabolic phenotypes of Irx3-deficient mice. 
Our data posit that IRX3 is a functional long-range target of obesity-associated variants within 
FTO, and represents a novel determinant of body mass and composition.
Noncoding variation in single nucleotide polymorphisms (SNPs) within a 47 kb region of 
high linkage disequilibrium (LD) in introns 1 and 2 of FTO remains the strongest genetic 
association with risk to polygenic obesity in humans 1–4. Individuals homozygous for risk 
alleles of the associated SNPs weigh approximately 3 kilograms more than individuals 
homozygous for non-risk alleles, underscoring the significant phenotypic impact of these 
common variants 2. Multiple follow-up studies directly implicated FTO as a gene 
controlling body mass and composition. Null Fto alleles in mice result in lean phenotypes, 
with reciprocal models overexpressing FTO displaying increased body weight 4–6. Lacking, 
however, is direct evidence that enhancers within the obesity-associated FTO introns are 
connected with regulation of FTO expression. Toward that end, expression quantitative trait 
locus (eQTL) analyses have systematically failed to show association between the obesity-
associated SNPs and FTO expression in human tissues 7–9.
To directly chart the cis-regulatory circuitry within the FTO locus, we used circular 
chromosome conformation capture followed by high throughput sequencing (4C-seq). We 
carried out 4C-seq in whole mouse embryos (E9.5) and in adult (8 weeks) mouse brains, 
since previous work suggest that brain FTO expression modulates metabolic 
parameters 6, 10. We profiled the genomic interactions with promoters of genes located 
within a megabase window around the obesity-associated SNPs (mm9, chr8:93,725,000–
94,725,000), including Fto and Rpgrip1l, and Irx3, a half-megabase downstream. The 
difference in interaction patterns among genes was striking (Fig. 1a). The Fto promoter 
chiefly participates in genomic interactions proximal to the gene promoter. While in mouse 
embryos these interactions include the obesity-associated intronic region (Fig. 1b), no such 
interactions are detected in adult mouse brains (Extended Data Fig. 1 and Supplementary 
Table 1). In marked contrast, the promoter of Irx3 participates in numerous long-range 
interactions across a broad genomic region encompassing nearly 2 megabases, including 
robust interactions with the obesity-associated interval within FTO (Fig. 1a). We confirmed 
these interactions between Irx3 and the Fto obesity-associated region using chromatin 
conformation capture (3C) in adult mouse brains (Extended Data Fig. 2c). These data 
suggest the obesity-associated interval is likely part of the regulatory landscape of Irx3. We 
next inferred that the long-range interactions between the obesity-associated FTO intron and 
IRX3 represent a conserved feature in vertebrate genomes. Inspecting the human ENCODE 
dataset, we observe that MCF-7 cells display the same pattern of long-range looping 
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between the obesity-associated interval and IRX3, but not FTO, assayed by ChIA-PET 
(Extended Data Fig. 2a). This is further corroborated by recent HiC data in human 
fibroblasts11 (Extended Data Fig. 2b). We also observed a similar pattern of chromatin 
interactions in zebrafish embryos, assayed by 4C-Seq (Extended Data Fig. 1c). Together, 
these data posit that the obesity-associated FTO intron is mediating functional interactions 
with IRX3 in the human, mouse, and zebrafish genomes.
Having uncovered evidence of direct looping between FTO intronic regions and IRX3, we 
next showed that enhancers within the obesity-associated interval possess functional 
characteristics compatible with IRX3 expression. We observed that the degree of 
evolutionary conservation in noncoding sequences of the FTO-IRX locus (chr16:53731249–
54975288) places it on the top 2% of similarly-sized genomic intervals, suggesting the 
presence of many functional noncoding elements spread over the region (see Methods). 
More specifically, ENCODE data suggest that the 47-kb obesity-associated interval is 
fraught with cis-regulatory elements, evidenced by an abundance of enhancer-associated 
chromatin marks, DNase hypersensitive sites, and transcription factor binding events across 
this genomic region (Fig. 1b). We tested three human DNA fragments from the 47-kb 
obesity-associated region for their putative enhancer properties using an in vivo mouse 
reporter assay. These fragments overlap enhancer-like chromatin marks in multiple cell 
lines. All three fragments displayed enhancer activity in neonatal (P0–P1) mice. 
Interestingly, two of the fragments drove strong reporter gene expression in lungs (Fig. 1b). 
Irx3 is highly expressed during lung development (Fig. 1b) 12, 13, whereas Fto expression in 
lungs is limited (Extended Data Fig. 3a and references 2, 14–16). Consistent with our data, a 
previous report has shown that the FTO obesity-associated region contains enhancers that 
drive Irx3-like expression in zebrafish 17.
Our data suggest that the regulatory landscape of IRX3 spreads over megabase distances, 
whereas FTO expression is primarily regulated by regions proximal to its promoter. To test 
this, we engineered a human Bacterial Artificial Chromosome (BAC) spanning 162 Kb of 
the FTO locus, including its promoter and the 47-Kb obesity-associated region (Extended 
Data Fig. 3). We recombineered a reporter cassette at the FTO translation start and 
generated transgenic mice harboring the engineered BAC. Transgenic mice expressed the 
reporter gene in multiple tissues, recapitulating the endogenous expression pattern of FTO14. 
We next determined that a 1.2 Kb region corresponding to the FTO promoter is sufficient to 
recapitulate most of the FTO expression pattern (Extended Data Fig. 3). In contrast, a 2.8-kb 
region corresponding to the IRX3 promoter does not recapitulate any of the endogenous 
expression patterns of IRX3, suggesting that IRX3 expression relies on long-range cis-
regulatory elements. A total of 15 human sequences in the broader FTO-IRX locus have 
been characterized as in vivo enhancers in mouse 17, 18, driving reporter expression in Irx3-
expressing tissues, including eye, limb, brain, neural tube, and branchial arches 12, 19 
(Supplementary Table 2). While these enhancers lie outside the obesity association interval, 
they are consistent with our chromatin looping data pointing to a broad Irx3 regulatory 
landscape, extending into Fto. Further supporting these findings, the genomic interval 
spanning FTO and IRX3 has been proposed to be part of a single genomic regulatory block, 
based on the presence of extended synteny across deep phylogenies and a high density of 
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highly conserved noncoding elements 17, as well as patterns of CTCF binding and chromatin 
interactions 20. Under these models, our data support the notion that the broad expression 
patterns of FTO are primarily regulated by elements proximal to the promoter, and that IRX3 
is endowed with an ancient, extensive cis-regulatory circuitry extending into FTO.
We next determined that gene expression studies in human brains corroborate our chromatin 
looping data, showing that the obesity-associated SNPs are associated with expression levels 
of IRX3, but not FTO. Our data and that of others 17 (Fig. 1b) demonstrate that the obesity-
associated SNPs overlap several in vivo enhancers, raising the possibility that allelic variants 
may disrupt enhancer activity and alter expression of their target gene(s). To test this, we 
carried out eQTL mapping in human brain samples. FTO and IRX3 are highly expressed in 
multiple regions of the brain including cerebellum and hypothalamus (Extended Data Fig. 
4). Utilizing a dataset of 153 brain samples from individuals of European ancestry 21, 
represented by cerebellum, we found significant association between 11 SNPs previously 
associated with increased body mass index (BMI), and expression of IRX3, but not FTO 
(Fig. 2a, Supplementary Table 3). These common SNPs have minor allele frequencies 
ranging from 42.5 to 47.5% and are in strong LD with each other (Extended Data Fig. 5). In 
all cases, such as for SNP rs9930506 (Fig. 2b), the allele associated with increased BMI is 
also associated with increased IRX3 expression. Further analysis, utilizing the GIANT 
Consortium dataset of SNPs associated with BMI in 249,796 individuals 22, reveals that 
among SNPs significantly associated with IRX3 expression in brain or adipose tissue, only 
those associated with IRX3 in brain show highly significant associations with BMI (Fig. 2c). 
Taken together, our data directly ties the noncoding genetic variation within FTO to tissue-
specific modulation of IRX3, but not FTO, expression in human brain.
Next, we exploited animal models to determine a potential role for IRX3 expression in the 
regulation of BMI and/or metabolism. Mice homozygous for an Irx3 null allele (Irx3KO) are 
viable and fertile, with no evidence of embryonic lethality. We observed a 25–30% 
reduction of body weight in Irx3KO mice compared to control littermates (wild-type; WT), 
independent of gender (Fig. 3a and Extended Data Fig. 6a, b and 7a, b). This difference 
becomes more pronounced if animals were subjected to a high-fat diet (HFD), with Irx3KO 
animals showing no significant body weight gain, contrasting to a 63% increase in control 
animals (Fig. 3a, b). Importantly, the percentage of fat mass in Irx3KO mice was 
significantly reduced without marked change of the lean mass ratio (Fig. 3c, d, and Extended 
Data Fig. 7c, d). Irx3KO mice exhibit marked reduction in adiposity with smaller fat depots 
as well as reduced adipocyte size (Fig. 3e and Extended Data Fig. 6b–d, 7e, f). These results 
were confirmed by differential gene expression of adiposity markers (i.e. leptin, adiponectin, 
and mcp1) in the Irx3KO perigonadal white adipose tissue (PWAT) (Extended Data Fig. 6e). 
Importantly, Fto expression was not altered in Irx3KO hypothalamus or PWAT, suggesting 
that the lean phenotype of Irx3KO mice is not associated with Fto (Fig. 3f). Since Irx3KO 
mice were resistant to HFD-induced obesity and metabolic disorder, such as hepatosteatosis 
(Fig. 3e), we examined glucose homeostasis by performing glucose tolerance tests (GTT) 
and insulin tolerance test (ITT) at different time points in the presence or absence of HFD. 
In 8-week old mice, no difference in GTT was found (Fig. 3g). While aging and HFD led to 
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glucose intolerance and insulin resistance in WT mice, Irx3KO mice showed none of these 
metabolic phenotypes (Fig. 3g–j).
Indirect calorimetric analysis showed higher energy expenditure in Irx3KO mice (Fig. 3k 
and Extended Data Fig. 8a, b & e). Importantly, Irx3KO mice show up-regulation of brown 
adipocyte markers in PWAT, including Ucp1, Ppargc1a, Prdm16, and Cidea, as well as 
increased expression of Adrb3 encoding the β3-adrenergic receptor, suggestive of elevated 
sympathetic activation (Fig. 3l). Furthermore, we found a significant increase of Ucp1 
expression in the brown adipose tissue (BAT) of Irx3KO mice (Extended Data Fig. 8e, f). 
WAT predominantly stores excessive calories and its accumulation causes obesity, while 
brown adipose tissue (BAT) dissipates energy (lipids and glucose) and has been the focus 
for potential development of novel therapeutic strategies to treat obesity and diabetes. Our 
data suggest that “browning” of WAT by higher sympathetic tone and activation of BAT 
might lead to increased energy expenditure in Irx3KO mice and partially account for their 
leanness and protection from diet-induced obesity.
Browning of WAT by increased sympathetic activity is a phenomenon controlled by 
hypothalamic circuits integrating central and peripheral metabolism regulation. Our human 
eQTL data suggest that the obesity-associated SNPs are associated with IRX3 expression in 
brain. We determined that Irx3 is expressed in the arcuate nucleus and median eminence of 
the hypothalamus, two critical regions involved in the regulation of energy homeostasis 
(Fig. 3m)23,24. To investigate a possible role of Irx3 expression in the hypothalamus 
mediating the body composition and energy homeostasis phenotypes in Irx3KO mice, we 
utilized Rosa26EnR-Irx3 conditional transgenic mice expressing a dominant negative form of 
Irx3 (EnR-Irx3) by crossing with Ins2-Cre (Extended Data Fig. 9a, b)23,25. This design 
allows for disrupting Irx3 function while preserving the architecture of genomic interactions 
between the Irx3 promoter and long-range regulatory sequences including the Fto obesity-
associated region. Remarkably, EnR-Irx3;Ins2-Cre mice phenocopy the physiological, 
histological, and molecular metabolism phenotypes of germline Irx3KO mice (Fig. 4a–d and 
Extended Data Fig. 9c, d). Energy expenditure was significantly higher in EnR-Irx3;Ins2-
Cre mice with similar food intake and locomotor activity (Fig. 4e and Extended Data Fig. 
10a–e). Notably, these mice also exhibited “browning” of WAT as well as activation of 
BAT (Fig. 4f and Extended Data Fig. 10f–g). Together, our data support the notion that the 
hypothalamic expression of Irx3 regulates energy homeostasis and body composition.
Our results do not dispute the notion emerging from animal models that Fto is also a 
regulator of body mass and composition. The functional link between FTO and body mass 
regulation originated from animal models, unequivocally demonstrating that variation in 
FTO expression results in variation in body mass phenotypes. But to assess the null 
expectation that genetic manipulations in mice may result in variation in these parameters, 
we searched among 7,556 targeted mouse gene knock-out models for evidence of alterations 
in body size, mass, and growth (See Methods). Nearly one third (2,166; 29%) of gene 
knock-outs in mice show alteration of these phenotypes, underscoring that animal models 
alone are not sufficient to definitively establish a functional relationship between a given 
gene and long-range noncoding variants (Supplementary Table 4). It is the aggregate of our 
data on chromatin looping, patterns of in vivo enhancer function, human eQTL mapping and 
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mouse model data that collectively place IRX3 as an important target gene of the genetic 
association with human obesity. These observations have direct implication on how to 
interpret the associations characterized for thousands of noncoding variants with human 
disease and related quantitative traits. We observe more than 150 genomic regulatory 
blocks, similar to that containing FTO and IRX3, overlapping with noncoding SNPs 
associated with human disease and complex traits in GWAS (Methods and Supplementary 
Table 5), highlighting the need for a careful experimental pipeline to define the target 
gene(s) for each disease-associated noncoding SNP.
Our data posit that the obesity-associated SNPs within FTO are functionally connected with 
regulation of IRX3 expression, and that IRX3 is an important determinant of body mass and 
composition. IRX3 encodes a transcription factor highly expressed in brain. While our data 
represent the first demonstration of the intersection of IRX3 biology with body mass 
composition and metabolism, previous work identified IRX3 overexpression in adipocytes as 
a hallmark of the molecular switch seen in patients after profound weight loss following 
bariatric surgery26. These data indicate that IRX3 may have important roles regulating 
metabolism beyond the ones we describe associated with Irx3 expression in hypothalamus. 
Future investigations will determine the precise molecular mechanisms by which IRX3 
regulates metabolic parameters.
Methods
3C
3C assays were performed as referred in27. Mouse brain tissue was processed to get single 
cells samples. 10 millions isolated cells were treated with lysis buffer (10 mM Tris-HCl pH 
8, 10 mM NaCl, 0.3% IGEPAL CA-630 (Sigma-Aldrich, I8896), 1X protease inhibitor 
cocktail (cOmplete, Roche, 11697498001)) and nuclei were digested with HindIII 
endonuclease (Roche, 10798983001). Subsequently, DNA was ligated with T4 DNA ligase 
(Promega, M1804). A set of locus specific primers (see table) was designed with the online 
program primer3 v. 0.4.028, each one close to a HindIII restriction site. These primers were 
used to make real time quantitative PCRs using a BioRad CFX96 Real Time System with 
SsoFast EvaGreen Supermix (BioRad 172-5203), in order to measure the relative 
enrichment in each ligation product. The primer designed within the LD-block was used as 
fixed primer. The quality of all primer pairs was measured using serial dilutions of a BAC 
DNA that encompass the regions of interest (RP23-268O10, RP23-96F3). PCR values were 
normalized by means of control primers designed in the Ercc3 gene locus. The average of 
four independent experiments was graphically represented.
4C-Seq
4C-seq assays were performed as previously reported27, 29–31. Whole embryos (9.5 days of 
development) or whole adult (8 weeks) mice brains (both strain CD-1; Charles River Labs) 
were processed to get approximately 10 million isolated cells, which were treated with lysis 
buffer (10 mM Tris-HCl pH 8, 10 mM NaCl, 0.3% IGEPAL CA-630 (Sigma-Aldrich, 
I8896), 1X protease inhibitor cocktail (cOmplete, Roche, 11697498001)). Nuclei were 
digested with DpnII endonuclease (New England Biolabs, R0543M) and ligated with T4 
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DNA ligase (Promega, M1804). Subsequently, Csp6I endonuclease (Fermentas, Thermo 
Scientific, FD0214) was used in a second round of digestion, and the DNA was ligated 
again. Specific primers were designed near each gene promoter with primer3. Viewpoint 
fragend coordinates were as follows: mFTO: chr8:93837310–93837724; mIrx3: 
chr8:94325277–94326009. Illumina adaptors were included in the primers sequence32. 16 
PCRs were performed with Expand Long Template PCR System (Roche, 11759060001) for 
each viewpoint, pooled together and purified using High Pure PCR Product Purification Kit 
(Roche, 11732668001). Quanti-iT™ PicoGreen dsDNA Assay Kit (Invitrogen, P11496) was 
used in order to measure sample concentration, and then they were sent for deep sequencing. 
4C-seq data were analysed, with some changes, as described in 30.
Briefly, raw sequencing data were de-multiplexed and aligned using either the Mouse July 
2007 (NCBI37/mm9) or Zebrafish December 2008 (Zv8/danRer6) assembly as the reference 
genome. Reads located in fragments flanked by two restriction sites of the same enzyme, or 
in fragments smaller than 40 bp were filtered out. Mapped reads were then converted to 
reads-per-1kb-bin units, and smoothed using a running mean 5-fragment window algorithm. 
To calculate the statistically significant targets for each viewpoint, a background theoretical 
model was calculated as the exponential fit curve of the average signal of 61 4C-Seq 
different samples33–35. The p-value for each bin was calculated by means of Poisson 
probability function. Smoothed data were uploaded to the UCSC Browser36 for visualization 
and plotted using the browser and Circos37. For plotting, statistically significant targets were 
defined as p<0.01. Data was submitted to GEO under accession GSE52830, and can be 
accessed online at http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?
token=elcraaeglhstzwz&acc=GSE52830.
Primers used for 3C experiments
3c_mouse_LDBlock TGGTCTCGGGTATCTTGTCC
3c_mouse_Irx3_control1 TCGCTCCTAGTGAGACTTTC
3c_mouse_Irx3_promoter TGATGTTGGTTCCTTACTAGG
3c_mouse_Irx3_control2 TCCACAGAAACATCTGACG
3c_mouse_Ercc3-1 TGACCTCCACACTCCTGAC
3c_mouse_Ercc3-2 ATGCGCAATTAGAAACTGC
Primers used for 4C-Seq experiments
4c_mouse_Fto_R AATGATACGGCGACCACCGAACACTCTTTCCCTACACGACGCTCTTCC GATCTCATATTGCTCTGGATGCAGATC
4c_mouse_Fto_NR CAAGCAGAAGACGGCATACGAGAACTACCCTTCCCAGAATGC
4c_mouse_Irx3_R AATGATACGGCGACCACCGAACACTCTTTCCCTACACGACGCTCTTCCGAT CTCCGCCGCGGAGCAGATC
4c_mouse_Irx3_NR CAAGCAGAAGACGGCATACGATGGAGTCGCCAATCACC
4c_zebrafish_Fto_R AATGATACGGCGACCACCGAACACTCTTTCCCTACACGACGCTCTTCCGAT CTCCTCTCACTGTCATCCGATC
4c_zebrafish_Fto_NR CAAGCAGAAGACGGCATACGACTACATTTTATGTCAGTTTCGGG
4c_zebrafish_Irx3a_R AATGATACGGCGACCACCGAACACTCTTTCCCTACACGACGCTCTTCCGAT CTCCTACCGGATTACTCTACAGATC
4c_zebrafish_Irx3a_NR CAAGCAGAAGACGGCATACGAAAAACGCCCAGAAGACTGAC
Note: R = read, NR = nonread
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ENCODE ChIA-PET
Publicly-available data for the breast cancer MCF7 cell line, generated by as part of the 
ENCODE project38 were downloaded from and visualized with the WashU EpiGenome 
Browser39 (http://epigenomegateway.wustl.edu/browser/). Li and colleagues40 performed 
ChIA-PET to capture long-range chromatin interactions associated with RNA polymerase II.
Locus conservation
To assess the level of high-level conservation of the FTO/IRX5 locus, we used phastCons41 
elements and scores as a measurement of conservation.
High-scoring phastCons elements (LOD > 680, top 1%) cover 3% (38,040/1,244,409 bp) of 
the genomic space that includes FTO and IRX5 (hg19, chr16:53731249–54975288), whereas 
on average, only 0.5% +− 0.6 of genomic intervals with the same length are occupied by 
such high-scoring phastCons elements. Genomic intervals of the same size of the FTO/IRX3 
locus were generated every 10kb for each chromosome. The FTO/IRX5 is at the top 1% 
intervals containing high-scoring phastCons elements.
Similarly, in the FTO/IRX5 interval, 9% of the base pairs have phastCons score above 0.9 
(range: 0.0–1.0), whereas 14,164 intervals from all chromosomes of the same size offset by 
200kb contain only 3.8% +− 1.9 of such high-scoring base pairs. At 9%, the FTO/IRX5 is at 
the top 2% intervals with the most conserved base pairs.
These results indicate that the FTO/IRX5 interval contains significantly more highly 
conserved base pairs than most genomic loci.
Enhancer reporter constructs, including the modified BAC, were created as previously 
reported42. The human (NCBI37/hg19) genomic coordinates of the elements cloned are: 
FTO-1: chr16:53800270–53805184; FTO-2: chr16:53808432–53813121; FTO-3: 
chr16:53816312–53821148. FTO-promoter: chr16:53736860–53738096; IRX3-promoter: 
chr16:54319963–54322782. BAC RP11-261B9 was modified by inserting a lacZ-Amp 
cassette in place of the 36 nucleotides in exon 1 at chr16:53,738,097–53,738,132. This 
homologous recombination was facilitated by using the following homology arms: FTO-
hArm1: chr16:53738047–53738096; FTO-hArm2: chr16:53738133–53738182.
Mouse in vivo transgenic reporter assays were performed as previously reported45
in situ hybridization assays were performed according to standard protocols43. The full 
length mouse Fto CDS used as riboprobe template was from IMAGE clone 5708558 
(ATCC, Manassas, Virginia).
Gene Expression in Human Tissues
For the eQTL analyses, we used cerebellum44 (n = 153; publicly available in GEO: 
GSE35974) and adipose45 (n=62; publicly available in GEO: GSE40234); details of the 
samples, the quality control procedure and the normalization approach used were previously 
described21. For adipose, the samples were chosen to be at the tails of the distribution of 
insulin sensitivity matched on age, gender and natural log of BMI. Because the adipose 
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samples included individuals of African ancestry, we performed principal component (PC) 
analysis and tested each marker in the locus for the additive effect of allele dosage on the 
residual expression phenotype (IRX3 and FTO) after adjusting for the PCs (n=2). Similarly, 
for cerebellum, we performed linear regression on the residual expression phenotype (IRX3 
and FTO) after adjusting for sex and pH to evaluate the additive effect of allele dosage at 
each marker in the locus; the non-diseased samples (obtained from the Stanley Medical 
Research Institute) included in the analysis were of European descent and thus the PCs were 
not used to generate the residual expression. Significance (p-value) was evaluated using the 
t-statistic from the regression.
eSNP Association with BMI
We downloaded genome-wide association data from the Genetic Investigation of 
Anthropometric Traits45 (GIANT) consortium website (http://www.broadinstitute.org/
collaboration/giant/index.php/GIANT_consortium_data_files#BMI_.28download_GZIP.
29). We extracted the p-values for those SNPs in the locus with significant association 
(p<0.05) with IRX3 or FTO expression in adipose or cerebellum. We plotted the distribution 
of association p-values for these expression-associated SNPs (eSNPs). rs9930506 is highly 
associated with BMI (p=1.41e-53, N=123541). Recombination rates are estimated from the 
International HapMap Project.
Statistical Analyses were done in the R statistical software (http://cran.r-project.org/). 
Regional plots were done by repurposing an R script retrieved from the Broad Institute 
(http://www.broadinstitute.org/diabetes/scandinavs/figures.html).
Mice
All animal experimental protocols approved by Animal Care Committee of the Toronto 
Centre of Phenogenomics conformed to the standards of the Canadian Council on Animal 
Care. Irx3-deficient (Irx3KO) mice 47 and Ins2-Cre mice 48 were described previously. 
Rosa26EnR-Irx3 conditional transgenic mice (EnR-Irx3) was generated using pROSA26PA 
gene-targeting vector as previously described 49. Mice were maintained on 12-hour light/
dark cycles and provided with food and water ad libitum. For diet-induced obesity studies, 8 
week old male mice were subjected to 45% high-fat diet (Research Diets) for 10 weeks. 
Body weight was measured every week from 4 to 18 weeks of age, and body composition 
was analyzed using a EchoMRI device (Echo Medical Systems) at 18 weeks of age. Body 
mass index (BMI) was calculated by dividing body weight (g) by body length (mm) squared 
(BMI = body weight/body length2).
Metabolic phenotyping experiments
Energy expenditure was evaluated via indirect calorimetry (Oxymax System, Columbus 
Instruments) over periods of 24 hour. Briefly, energy expenditure was calculated by 
multiplying oxygen consumption (VO2) by the calorific value (CV = 3.815 + 1.232 × 
respiratory exchange ratio) and corrected by lean mass. Locomotor activity and food intake 
were also measured simultaneously. For glucose and insulin tolerance tests, mice were 
subjected to intraperitoneal bolus injection of glucose (1mg/g of body weight) or insulin 
(1.5mU/g) after fasting for overnight (14–16 hours) or 6 hours with water ad libitum, 
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respectively. Blood glucose levels were measured at the indicated intervals. For histological 
analysis, tissues were fixed in 4% paraformaldehyde and embedded in paraffin. 5 μm 
sections were stained with hematoxylin and eosin (H&E). Irx3 expression in brain and lung 
was examined using Irx3lacZ knockin mice with beta-galactosidase staining.
Gene and protein expression analyses
Total RNA was extracted from fat tissues or hypothalamus using RNeasy Lipid Tissue Kit 
(Qiagen), and cDNA was synthesized from 2 μg of RNA using M-MLV reverse 
transcriptase (Invitrogen) with oligo(dT). Gene expression assay was conducted using 
SYBR Green methods on Viia7 (Applied Biosystems), and relative Ct values were 
normalized by β-actin. Primer sequences are available upon request.
Western blot analysis was performed as previously described 50. The same amount of 
protein extracted from hypothalamus or brown adipose tissues was loaded, which was 
confirmed by β-actin as a loading control. Antibodies used are as follows: Ucp1 (Santa Cruz 
Biotechnology), Irx3 (generated in-house), and β-actin (Calbiochem).
Statistics
All results are expressed as mean ± S.E.M. Statistical significance of differences among 
groups was determined by Student’s t-test or ANOVA with post hoc analysis, Student-
Newman-Keuls using Sigma Stat (SPSS Inc., Chicago, IL). Differences at P < 0.05 were 
considered statistically significant (*, P < 0.05 vs. WT or control; #, P < 0.05 vs. WT, 
HFD). Following numbers of mice/samples were used for comparison; Body weight 
measurement for Irx3 mice (ND, WT/KO: n = 32/25; HFD, WT/KO: n = 12/7) and EnR-
Irx3 mice (control/mutant: n = 9/12); Body composition analysis for Irx3 mice (ND 
WT/KO: n = 21/12; HFD WT/KO: n = 8/5) and EnR-Irx3 mice (control/mutant: n = 9/12); 
Glucose tolerance test for Irx3 mice (ND 8wk, WT/KO: n = 8/5; ND 18wk, WT/KO: n = 
10/6; HFD 18wk, WT/KO: n = 12/7) and EnR-Irx3 mice (control/mutant: n = 5/8); Insulin 
tolerance test for Irx3 mice (WT/KO: n = 12/7); Indirect calorimeter analysis for Irx3 
mice(ND WT/KO: n = 7/5; HFD WT/KO: n = 8/4) and EnR-Irx3 mice(control/mutant: n = 
5/7), and Gene expression analysis for Irx3 mice (WT/KO: n = 10/7) and EnR-Irx3 mice 
(control/mutant: n = 5/7).
Mouse Body Mass Phenotypes
To calculate the fraction of knockout mice that display a phenotype affecting body mass, we 
consulted the Mouse Genome Informatics (MGI) database51.
First, to determine the number of gene knockouts that result in a body mass phenotype, we 
needed to define a more precise phenotype. The Mammalian Phenotype Ontology52 (http://
www.informatics.jax.org/searches/MP_form.shtml) specifies a controlled vocabulary by 
which all mice in the MGI database are classified. Within this framework, (we believed) the 
most applicable is “abnormal postnatal growth/weight/body size” (MP:0002089).
Next, we crafted a query using the MouseMine portal53 (http://www.mousemine.org) to 
access the MGI database, using MP:0002089 as the search criteria in the “Mammalian 
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phenotypes --> Mouse genotypes” template (http://www.mousemine.org/mousemine/
template.do?name=MPhenotype_MFeature&scope=all). We asked for all targeted alleles on 
chromosomes 1–19, X and Y, reasoning that many non-targeted (i.e. random, chemical and 
radiation-induced) mutations have not been precisely mapped, making it difficult if not 
impossible to ensure that they are not counted multiple times. Also, in the context of our 
study, we are discussing the chance that a targeted knockout would give a specific 
phenotype, so these types of alleles are most relevant. Finally, we excluded alleles present 
only as cell lines, resulting in 2166 unique genes.
To determine the total number of targeted mutations present in the MGI database, we 
performed a search identical to that above but omitting the MP:0002089 term, resulting in 
7556 unique genes.
Genomic Regulatory Blocks
Genomic regulatory blocks are regions under strong selection that contain a number of 
syntenic highly conserved sequences, believed to regulate a syntenic target gene (“anchor 
gene”, the gene that is the raison d’être of the GRB). There are different approaches to 
determine GRBs, usually identifying syntenic genes and non-coding conserved regions that 
span a region and determining the boundaries of the region.
GWAS identified SNPs that might affect non-coding regulatory elements that, by their turn, 
regulate specific target genes. Assignment of regulatory elements to targets is still a 
challenge, the simplest method being to assign them to the nearest gene. In the case of FTO, 
because the GWAS SNP occurs in an FTO intron, this gene was considered to be the target.
The notion put forward here is that when regulatory elements occur within a GRB, which is 
the case for FTO/IRX3/IRX5, it is likely that they target the anchor gene (IRX3/IRX5), 
given its importance. Supplemental Table 5 contains an annotation of GRBs and their 
anchor genes and the GWAS SNPs within the GRB as well as annotation regarding whether 
the nearest gene is the anchor gene or not. In those cases in which the nearest gene differs 
from the anchor gene, we propose that the anchor gene be used as the putative target and 
additional experimentation as shown in this work should be performed to precisely 
determine which is the target gene for the GWAS-affected regulatory element.
Genomic regulatory blocks were obtained from UCNEbase (http://ccg.vital-it.ch/
UCNEbase/)54. Human UCNE clusters (hg19) were downloaded from http://ccg.vital-it.ch/
UCNEbase/data/download/clusters/hg19_clusters_coord.bed and are referred here as GRBs.
The hg19 GWAS catalog from the UCSC Genome browser was downloaded and the tagging 
SNPs contained in GRBs with more than 1 gene (making SNP assigning doubtful) were kept 
for further annotation. SNPs occurring in exons were removed. The nearest gene was 
considered to be the RefSeq gene whose transcription start site was the nearest, or the gene 
where the SNP is contained.
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Extended Data
Extended Data Figure 1. Long range interactions in mouse and zebrafish
4C-seq data for the Irx3/Fto locus, visualized with the UCSC genome browser. a, Data (also 
shown in the circular plot in Fig. 1) generated using whole mouse embryos (E9.5), showing 
the frequency of interactions with the promoter of Irx3 (blue, top) or Fto (magenta, bottom). 
The background signal corrects for the strong correlation between (non-specific) ligation 
events and the linear distance along the chromosome. Poisson statistical significance (-log 
(p-value)) of the 4C-seq interactions over the background is plotted. Significant interactions 
(p<0.01), “targets,” are displayed in black. b, as above but for adult mouse brain (8 wks). c, 
as above for whole zebrafish embryos (24hrs post fertilization). In all, the region 
orthologous to the obesity association interval in the first intron of Fto is highlighted in pink.
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Extended Data Figure 2. Long-range interactions at the FTO/IRX3 locus
a, ENCODE data for ChIA-PET using RNA polymerase 2 (POL2) in MCF7 (human breast 
adenocarcinoma) cells shows interactions between IRX3 and the obesity association interval 
in the first intron of FTO. No interactions are observed between the FTO promoter and the 
association interval. This public data is available from and was visualized with the WashU 
EpiGenome Browser (http://epigenomegateway.wustl.edu/browser/). b, Hi-C data 
previously generated{Jin, 2013 #49} in human IMR-90 (fetal lung) cells. In the association 
interval, the IRX3 signal is stronger than the background (random) signal. However, the 
signal for FTO is not. c, 3C data generated with adult (8 wks) mouse brain. Using bait (red 
circle) in the association interval (red rectangle), we observe more frequent interactions with 
the Irx3 promoter compared to control regions 1 and 2 that are 29 and 42 kb away, 
respectively, indicative of looping.
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Extended Data Figure 3. Gene expression in mouse tissue
a, FTO expression in lung and brain, shown by RNA in situ hybridization for mouse Fto 
mRNA, in newborn (P1) mouse. Lungs and heart (left, whole organs) were processed 
simultaneously and in the same well as brain (right, sagittal section) so that the relatively 
higher expression in brain can be observed. b, LacZ staining for beta-galactosidase 
expression driven from the human FTO promoter. At top, the promoter-lacZ fusion is in the 
context of 162kbp of human genomic sequence carried in a bacterial artificial chromosome 
(BAC) containing the first three exons of FTO, the entire obesity-associated interval and any 
enhancers present. The broad expression is consistent with previous reports in human and 
mouse (see main text for references). At bottom, the promoter-lacZ construct is isolated: 
only the 1,237 bp proximal to the transcriptional start site are included. Broad expression is 
recapitulated, indicating the robust transcriptional competency of the human FTO promoter. 
c, In contrast, the 2,820 bp proximal human IRX3 promoter is not sufficient to drive lacZ 
expression, which is consistent with an enhancer-dependent transcriptional control 
mechanism.
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Extended Data Figure 4. IRX3 expression in human brain
a, IRX3 expression in human tissues including brain. Expression data, measured on 
Affymetrix HG-U133 arrays, were obtained from the Body Atlas, Tissues, at http://
www.nextbio.com. The median expression across all 128 human tissues from 1,068 arrays is 
shown by the red line. b, IRX3 expression in 11 different regions of human brain. Data were 
retrieved from Human Brain Transcriptome data at http://www.molecularbrain.org. 
Abbreviations: Amyg: amygdala; Caud nuc: caudate nucleus; Cere: cerebellum; Corp Call: 
corpus callosum; DRG: dorsal root ganglion; Frnt Cort: frontal cortex; Hippo: hippocampus; 
Hypo: hypothalamus; Pit: pituitary; Spine: spinal cord; Thal: thalamus.
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Extended Data Figure 5. Linkage Disequilibrium in FTO
LD plot from HapMap phase II European dataset, visualized in the UCSC browser. LD 
blocks are outlined in black. Obesity-associated SNPs from the National Human Genome 
Research Institute (NHGRI) GWAS catalog are shown above, in green, demonstrating why 
this LD block is considered to define the “association interval.
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Extended Data Figure 6. Irx3KO male mice are leaner with reduced adiposity
a, Representative photograph of WT and Irx3KO mice fed ND at 18 weeks of age. b, 
Representative anatomical views of WT and Irx3KO mice fed ND. Yellow dotted lines 
depict subcutaneous IWAT (left) and visceral PWAT (right). c, Tissue weights as a 
percentage of body weight showed smaller fat pad sizes in Irx3KO mice, compared to WT 
mice, in both ND and HFD conditions. (ND, WT/KO: n = 20/12; HFD, WT/KO: n = 8/5). 
Data are mean ± s.e.m. (*, P < 0.05 vs. WT, ND; #, P < 0.05 vs. WT, HFD). d, 
Representative H&E sections of PWAT, IWAT, and BAT from ND-fed mice demonstrated 
smaller adipocyte size in Irx3KO mice than control. e, qPCR of WT and Irx3KO PWAT for 
the indicated marker genes: Leptin (lep) and adiponectin (adipoq) are adipogenic markers, 
positively and negatively associated with adiposity, respectively; Monocyte chemoattractant 
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protein-1 (Mcp1) correlate positively with adiposity. (*, P < 0.05 vs. the corresponding with 
WT value) (WT/KO: n = 10/7).
Extended Data Figure 7. Irx3KO female mice are leaner with reduced adiposity
a, Body weight (BW) changes of WT and Irx3KO female mice fed a normal diet (ND). 
(WT/KO: n = 15/14). b, BMI, calculated by BW/body length2 (BL), is lower in Irx3KO 
female mice. (WT/KO: n = 7/7). c–d, body composition analysis showed reduced fat mass 
and to a less extent lean mass in Irx3KO female mice compared to WT mice, leading to 
decreased fat mass ratio. (WT/KO: n = 9/8). e, Representative H&E-stained sections of 
mammary gland (MG) WAT and periovarian (PO) WAT revealed smaller adipocyte size in 
Irx3KO female mice, compared to WT. f, MGWAT and BAT weights as a percentage of 
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body weight. (WT/KO: n = 4/5). Data are mean ± s.e.m. (*, P < 0.05 vs. the corresponding 
with WT value)
Extended Data Figure 8. Higher energy expenditure of Irx3KO mice
a, Energy expenditure, corrected for lean mass (kcal/kg/hr), over 24 hour period of 18 week 
old WT and Irx3KO mice fed with ND and HFD. (ND WT/KO: n = 7/5; HFD WT/KO: n = 
8/4). b, Locomotor activity of WT and Irx3KO mice. c, Average amount of food intake over 
24 hour period with or without normalization to lean mass. d, Average locomotor activity 
measured over 24 hours. e–f, Elevated Ucp1 gene and protein expression in BAT. (WT/KO: 
n = 7/6). Data are mean ± s.e.m. *, P < 0.05 vs. the corresponding with WT value.
Extended Data Figure 9. Hypothalamic-specific Irx3 dominant negative mice are leaner with 
reduced adiposity
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a, Schematic diagram of generation of transgenic mice overexpressing dominant-negative 
Irx3 in the hypothalamus. b, Immunoblotting showed EnR-Irx3 expression in the 
hypothalamus of mutant mice without affecting endogenous Irx3 expression, compared to 
control mice. c, Tissue weights as a percentage of body weight showed that fat pad sizes are 
smaller in mutant mice, compared to control mice. d, Reduced leptin expression and 
increased adiponectin gene expression in PWAT of mutant mice. (control/mutant: n = 5/7). 
Data are expressed as mean ± s.e.m. *, P < 0.05 compared to control group.
Extended Data Figure 10. Higher energy expenditure of Hypothalamic dominant negative Irx3 
mice
a, Energy expenditure, corrected for lean mass (kcal/kg/hr), over 24 hour period of 18 week 
old mice. b, Locomotor activity. c–d, Average amount of food intake over 24 hour period 
with or without normalization to lean mass. e, Average locomotor activity measured over 24 
hours. f–g, Elevated gene and protein expression of Ucp1 in BAT of mutant mice. (control/
mutant: n = 5/7). Data are expressed as mean ± s.e.m. *, P < 0.05 compared to control 
group.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Long-range interactions in the IRX3/FTO locus
a, Mouse embryo 4C-seq interactions emanating from each promoter are displayed as links 
across the circle (darker link implies greater significance). Outer plots show significance of 
interactions above background (-log(p-value)). The obesity-associated interval is highlighted 
red. b, Magnified view of the association interval. Contained within are the orthologous 
locations of obesity-associated SNPs (black pips), and epigenetic marks associated with 
regulatory elements. Endogenous Irx3 expression is shown (1. lung, 2. brain) in Irx3lacZ 
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knockin mouse. Three enhancers (rectangles 3–5) drive reporter expression in lungs (3, 5) 
and brain (4). Other enhancers17 are shown in black.
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Figure 2. BMI-associated SNPs are eSNPs for IRX3, not FTO, expression in human brain
a, SNPs associated with BMI in the FTO locus. 43 SNPs associated with IRX3 expression 
(eSNPs) are shown in red, including 11 also associated with BMI. No SNPs are associated 
with FTO expression (p-value>0.05). Arrowheads: IRX3 eSNPs outside the obesity-
associated region (pink); arrow: rs9930506. b, In cerebellum, the allele of rs9930506 
associated with increased BMI (risk allele) is correlated with increased IRX3 expression and 
not with FTO expression. c, Histogram plotting the number of SNPs associated with IRX3 
expression in adipose (black) and brain (red) (y-axis) by the significance of their association 
with BMI (x-axis). Full statistical details in Methods.
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Figure 3. Irx3 deficient mice are leaner and are protective against diet-induced obesity
a, Body weight in wild-type (WT) and Irx3KO mice fed normal (ND) or high-fat diet 
(HFD). b, Weight gain in ND or HFD. c, Fat and lean mass in WT and Irx3 KO mice. d, Fat 
and lean mass ratio as a percentage of body weight. e, Sections of inguinal white adipose 
tissue (IWAT; subcutaneous), perigonadal WAT (PWAT; visceral), brown adipose tissue 
(BAT), and liver from HFD-fed mice. f, Fto mRNA expression in hypothalamus and PWAT 
of Irx3 KO and WT mice.g-i, Glucose tolerance tests (GTT) in WT and Irx3 KO mice. Inset 
graphs show area under curve (AUC). j, Insulin tolerance test (ITT) in HFD-fed mice. k, 
Energy expenditure on ND- and HFD-fed mice. l, Gene expression in PWAT. m, Irx3 
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expression in the arcuate nucleus and median eminence. Left panel shows a ventral view of 
whole-mount stained brain. A dashed red line indicates the position of cross-section, 
displayed in the right panel. β-gal stained area in arcuate nucleus is marked by black line. 
HP, hypothalamus; OC, optic chiasm; MEm, median eminence; 3V, third ventricle. Data are 
expressed as mean ± s.e.m. *, P < 0.05 compared to control group. See additional statistical 
detail in Methods.
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Figure 4. hypothalamus-specific dominant negative Irx3 mice recapitulate the metabolic 
phenotype of Irx3 deficient mice
a, Body weight of control (EnR-Irx3) and mutant mice (EnR-Irx3;Ins2-Cre) fed normal diet. 
b, Fat and lean mass ratio as a percentage of body weight.. c, H&E-stained sections of 
IWAT, PWAT and BAT. d, Glucose tolerance test. e, Energy expenditure corrected for lean 
mass (kcal/kg/hr). f, qPCR in PWAT in control and mutant mice. Data are expressed as 
mean ± s.e.m. *, P < 0.05 compared to control group. Additional detail in Methods.
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